

Supporting Information for
Preparation of 3-azoindoles and
3-hydrazoneindolin-2-imines as well as their applications as
NNO pincer ligands for boron

Hualong Ding, Zhixing Peng, Jinjin Wang, Ping Lu,* Yanguang Wang*

Department of Chemistry, Zhejiang University, Hangzhou 310027, P. R. China

pinglu@zju.edu.cn; orgwyg@zju.edu.cn

Contents

General Information

References

General Procedure for the Synthesis of **3,4,7**

The ORTEP diagram and Crystal Parameters of **3a,4l,7a**

Characterization Data for Products

The ^1H and ^{13}C NMR Spectra of compound **3, 4, 7**

Figure S1 Absorption spectra of **3** in DCM

Figure S2 Absorption spectra of **7** in DCM

General Information


NMR spectra were recorded on 400MHz, 500MHz, or 600MHz spectrometer. The chemical shifts for ¹H NMR spectra were reported relative to internal TMS (0 ppm) in CDCl₃ or (CD₃)₂SO. The following abbreviations were used to describe peak patterns when appropriate: b = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. Coupling constants(*J* values) were reported in Hertz (Hz). ¹³C NMR spectra were recorded on 100MHz, 125MHz, or 150MHz spectrometerand the chemical shifts were referenced to the central line of the triplet of CDCl₃(77.27 ppm) or the center line of the heptet of (CD₃)₂SO (40.0 ppm). Infrared spectra were obtained on BRUKERVECTOR 22 spectrometer. Absorption spectra were obtained on SHIMAZU UV-Visible (UV-2450) spectrophotometer. High-resolution mass spectra (HRMS) data wererecorded onanMatrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) mass spectrometer and Agilent Technologies 6224 TOF LC/MS apparatus (ESI). Melting points were recorded on a SGW X-4.

Compounds **2** were prepared according to the published methods.^{1,2} Compounds **5** and **6** were purchased from chemical companies.

References


1. Y. P. Xing, G. R. Sheng, J. Wang, P. Lu, and Y.G. Wang, Org. Lett. 2014, 16, 1244–1247.
2. G. R. Sheng, K. Huang, Z. H. Chi, H. L. Ding, Y. P. Xing, P. Lu, and Y. G. Wang, Org. Lett., 2014, 16, 5096–5099

General Procedure for the Synthesis of **3**




To a stirred suspension of **2**(0.25 mmol), K_2CO_3 (69 mg) in DMSO (5 mL) was added **5**(0.275 mmol) at room temperature. Then the reaction mixture was stirred for 3h. After the reaction completed, the mixture was washed with diluted HCl, extracted with DCM, dried over anhydrous Na_2SO_4 , then filtered and concentrated. The residue was purified by column chromatography over silica gel with hexane/DCMas the eluent to give **3**.

General Procedure for the Synthesis of **4**




To a stirred solution of **2**(0.25 mmol), K_2CO_3 (104 mg) in DMSO (5 mL) at N_2 was added **6** via syringe at room temperature. After the reaction completed (checked by TLC), the mixture was washed with diluted HCl, extracted with DCM, dried over anhydrous Na_2SO_4 , then filtered and concentrated. The residue was purified by column chromatography over silica gel with hexane/EtOAc as the eluent to give compound **4**.

General Procedure for the Synthesis of 7



To a stirred solution of **3**(0.25 mmol) in DCM (5mL) under N_2 atmosphere was added $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (1.6 ml) and DIEA (1.4 mL) via syringe at room temperature. The reaction mixture was stirred for about 9h at room temperature. After the reaction completed, the mixture was concentrated under reduced pressure. The residue was purified by column chromatography over silica gel with hexane/DCMas the eluent to give **7**.

The ORTEP diagram and Crystal Parameters of **3a**




Bond precision: C-C = 0.0039 Å Wavelength=0.71073
 Cell: a=8.2558(6) b=10.1328(7) c=13.9082(11)
 alpha=77.492(6) beta=79.130(6) gamma=85.572(6)
 Temperature: 293 K

	Calculated	Reported
Volume	1114.69(15)	1114.69(14)
Space group	P -1	P -1
Hall group	-P 1	-P 1
Moiety formula	C ₂₆ H ₂₂ N ₄ O ₃ S	C ₂₆ H ₂₂ N ₄ O ₃ S
Sum formula	C ₂₆ H ₂₂ N ₄ O ₃ S	C ₂₆ H ₂₂ N ₄ O ₃ S
Mr	470.54	470.54
Dx, g cm ⁻³	1.402	1.402
Z	2	2
Mu (mm ⁻¹)	0.183	0.183
F000	492.0	492.0
F000'	492.44	
h, k, lmax	9, 12, 16	9, 12, 16
Nref	4069	4054
Tmin, Tmax	0.957, 0.968	0.770, 1.000
Tmin'	0.955	

Correction method= MULTI-SCAN
 Data completeness= 0.996 Theta(max)= 25.350
 R(reflections)= 0.0505(2928) wR2(reflections)= 0.1446(4054)
 S = 1.031 Npar= 310

The ORTEP diagram and Crystal Parameters of 4l



Bond precision: C-C = 0.0048 Å

Wavelength=0.71073

Cell: a=33.094 (3) b=9.7382 (7) c=15.8855 (11)
 alpha=90 beta=96.540 (7) gamma=90

Temperature: 293 K

	Calculated	Reported
Volume	5086.2 (7)	5086.3 (7)
Space group	C 2/c	C 1 2/c 1
Hall group	-C 2yc	-C 2yc
Moiety formula	C26 H26 N4 O4 S	C26 H26 N4 O4 S
Sum formula	C26 H26 N4 O4 S	C26 H26 N4 O4 S
Mr	490.57	490.57
Dx, g cm-3	1.281	1.281
Z	8	8
Mu (mm-1)	0.166	0.166
F000	2064.0	2064.0
F000'	2065.85	
h,k,lmax	39,11,19	39,11,19
Nref	4666	4653
Tmin, Tmax	0.951, 0.963	0.965, 1.000
Tmin'	0.951	

Correction method= MULTI-SCAN

Data completeness= 0.997

Theta (max)= 25.350


R(reflections)= 0.0531(2775)

wR2 (reflections)= 0.1563(4653)

S = 1.020

Npar= 319

The ORTEP diagram and Crystal Parameters of 7a



Bond precision: C-C = 0.0033 Å

Wavelength=0.71073

Cell: $a=11.8786(8)$ $b=14.6539(7)$ $c=14.7921(10)$
 $\alpha=90$ $\beta=112.989(8)$ $\gamma=90$

Temperature: 293 K

	Calculated	Reported
Volume	2370.3(3)	2370.3(3)
Space group	P 21/n	P 1 21/n 1
Hall group	-P 2yn	-P 2yn
Moiety formula	C26 H20 B F N4 O3 S	C26 H20 B F N4 O3 S
Sum formula	C26 H20 B F N4 O3 S	C26 H20 B F N4 O3 S
Mr	498.33	498.33
Dx, g cm ⁻³	1.396	1.396
Z	4	4
μ (mm ⁻¹)	0.182	0.182
F000	1032.0	1032.0
F000'	1032.95	
h, k, lmax	14, 17, 17	14, 17, 17
Nref	4332	4317
Tmin, Tmax	0.926, 0.943	0.888, 1.000
Tmin'	0.926	

Correction method= # Reported T Limits: Tmin=0.888 Tmax=1.000
AbsCorr = MULTI-SCAN

Data completeness= 0.997

Theta (max)= 25.340

R(reflections)= 0.0399(3352)


wR2(reflections)= 0.1057(4317)

S = 1.017

Npar= 327


Characterization Data for Products

(E)-N-(3-((2-Hydroxynaphthalen-1-yl)diazenyl)-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide(3a)



Blacksolid (115 mg, 98%); m.p. 174.9-175.8°C; ^1H NMR (400 MHz, CDCl_3) δ 12.67 (b, 1H), 11.22 (s, 1H), 7.92 (d, $J = 8.4$ Hz, 2H), 7.69 - 7.67 (m, 2H), 7.51 (d, $J = 8.8$ Hz, 1H), 7.40 - 7.36 (m, 1H), 7.27 - 7.20 (m, 4H), 7.16 (d, $J = 8.8$ Hz, 2H), 6.95 - 6.91 (m, 2H), 4.02 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 146.8, 144.0, 141.0, 139.7, 123.0, 128.7, 128.5, 128.1, 127.4, 127.2, 127.1, 126.7, 126.5, 125.0, 124.2, 123.7, 121.2, 120.4, 120.0, 118.8, 118.3, 110.4, 33.5, 21.7; IR (KBr) ν 3451, 3167, 3058, 1591, 1556, 1471, 1372, 1284, 1144, 1085, 805 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{26}\text{H}_{23}\text{N}_4\text{O}_3\text{S}]^+$:471.149; found:471.149.


(E)-N-(3-((2-Hydroxynaphthalen-1-yl)diazenyl)-1-methyl-1H-indol-2-yl)benzenesulfonamide(3b)



Reddish-brown solid (116 mg, 99%); m.p. 184.3-185.1°C; ^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}$) δ 13.05 (s, 1H), 11.46 (b, 1H), 8.64 (d, $J = 8.4$ Hz, 1H), 8.41 - 8.39 (m, 1H), 7.91 - 7.86 (m, 2H), 7.74 - 7.72 (m, 2H), 7.68 (t, $J = 7.6$ Hz, 1H), 7.61 - 7.60 (m, 1H), 7.48 - 7.42 (m, 6H), 7.17 (d, $J = 8.8$ Hz, 1H), 3.62 (s, 3H); ^{13}C NMR (100 MHz, $(\text{CD}_3)_2\text{SO}$) δ 149.7, 140.2, 135.6, 134.9, 133.6, 132.4, 131.9, 129.7, 129.2, 128.8, 128.6, 128.1, 127.6, 127.3, 125.2, 124.4, 124.0, 121.9, 121.8, 120.1, 117.5, 111.6,


30.4; IR (KBr) ν 3452, 3179, 3058, 1592, 1553, 1467, 1371, 1297, 1156, 1086, 796 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₅H₂₁N₄O₃S]⁺:457.133; found:457.133.

(E)-4-Fluoro-N-(3-((2-hydroxynaphthalen-1-yl)diazenyl)-1-methyl-1H-indol-2-yl)benzenesulfonamide(3c)



Blacksolid (117 mg, 99%); m.p. 173.3-174.1°C; ¹H NMR (400 MHz, (CD₃)₂SO) δ 12.80 (s, 1H), 11.51 (b, 1H), 8.65(d, J = 8.0 Hz, 1H), 8.40 - 8.38 (m, 1H), 7.91 - 7.86 (m, 2H), 7.78 - 7.75 (m, 2H), 7.70 - 7.63 (m, 2H), 7.48 - 7.43 (m, 3H), 7.23 (t, J = 8.0 Hz, 2H), 7.15 (d, J = 8.4 Hz, 1H), 3.72 (s, 3H); ¹³C NMR (100 MHz, (CD₃)₂SO) δ 165.1 (d, $^1J_{CF}$ = 250 Hz), 149.4, 136.5, 135.7, 134.9, 132.4, 131.8, 130.5 (d, $^3J_{CF}$ = 9 Hz), 129.1(d, $^4J_{CF}$ = 3 Hz), 128.8, 128.6, 128.1, 127.5, 125.3, 124.5, 124.1, 121.9, 121.8, 119.9, 117.5, 116.8 (d, $^2J_{CF}$ = 24 Hz), 111.6, 30.5; IR (KBr) ν 3452, 3188, 3070, 1624, 1555, 1467, 1371, 1286, 1147, 1085, 795 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₅H₂₀FN₄O₃S]⁺:475.124; found:475.123.


(E)-4-Chloro-N-(3-((2-hydroxynaphthalen-1-yl)diazenyl)-1-methyl-1H-indol-2-yl)benzenesulfonamide(3d)



Blacksolid (116 mg, 95%); m.p. 173.2-174.5°C; ¹H NMR (400 MHz, (CD₃)₂SO) δ 12.70 (s, 1H), 11.57 (b, 1H), 8.64 (d, J = 7.2 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 7.91 - 7.86 (m, 2H), 7.69 - 7.63 (m, 4H), 7.48 - 7.42 (m, 5H), 7.16 (d, J = 8.8 Hz, 1H), 3.74(s,


3H); ^{13}C NMR (100 MHz, $(\text{CD}_3)_2\text{SO}$) δ 149.3, 138.8, 135.7, 134.7, 132.4, 131.9, 129.7, 129.2, 128.7, 128.6, 128.1, 127.5, 125.3, 124.4, 124.1, 121.9, 121.8, 119.9, 117.5, 111.6, 30.5; IR (KBr) ν 3436, 3185, 3057, 1578, 1470, 1375, 1305, 1147, 1087, 1002, 798 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{25}\text{H}_{20}\text{ClN}_4\text{O}_3\text{S}]^+$:491.094; found:491.094.

(E)-N-(3-((2-Hydroxynaphthalen-1-yl)diazenyl)-1-methyl-1H-indol-2-yl)methane sulfonamide(3e)



Orange powder (93 mg, 94%); m.p. 165.0-166.2°C; ^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}$) δ 13.22 (b, 1H), 11.67 (b, 1H), 8.89 (d, $J = 7.2$ Hz, 1H), 8.36 (s, 1H), 7.92 (d, $J = 8.0$ Hz, 1H), 7.87 (d, $J = 8.8$ Hz, 1H), 7.73 - 7.69 (m, 1H), 7.58 (d, $J = 3.2$ Hz, 1H), 7.50 - 7.43 (m, 3H), 7.29 (d, $J = 8.8$ Hz, 1H), 3.87 (s, 3H), 3.28 (s, 3H); ^{13}C NMR (100 MHz, $(\text{CD}_3)_2\text{SO}$) δ 148.9, 138.2, 136.9, 131.4, 130.5, 128.9, 128.9, 128.1, 127.1, 125.8, 124.5, 124.1, 122.3, 121.2, 119.6, 118.6, 111.5, 42.6, 31.2; IR (KBr) ν 3452, 3264, 3022, 1576, 1546, 1469, 1371, 1324, 1157, 982, 817 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{20}\text{H}_{19}\text{N}_4\text{O}_3\text{S}]^+$:395.117; found:395.118.


(E)-N-(3-((2-Hydroxynaphthalen-1-yl)diazenyl)-1-methyl-1H-indol-2-yl)naphthalene-2-sulfonamide(3f)



Reddish-brown powder (124 mg, 98%); m.p. 160.1-161.3°C; ^1H NMR (400 MHz,


$(CD_3)_2SO$) δ 12.87 (s, 1H), 11.49 (b, 1H), 8.51 (d, $J = 8.4$ Hz, 1H), 8.40 (s, 1H), 8.37 - 8.35 (m, 1H), 8.00 (d, $J = 7.6$ Hz, 1H), 7.90 (d, $J = 8.8$ Hz, 1H), 7.85 (d, $J = 8.0$ Hz, 1H), 7.76 (d, $J = 9.2$ Hz, 1H), 7.72 - 7.59 (m, 4H), 7.46 - 7.41 (m, 5H), 6.91 (d, $J = 8.4$ Hz, 1H), 3.66 (s, 3H); ^{13}C NMR (100 MHz, $(CD_3)_2SO$) δ 149.3, 137.2, 135.6, 134.9, 134.7, 132.2, 132.1, 131.8, 129.7, 129.6, 129.1, 128.6, 128.5, 128.5, 127.9, 127.7, 127.7, 125.1, 124.3, 124.0, 122.6, 121.9, 121.7, 119.9, 117.5, 111.6, 30.4; IR (KBr) ν 3451, 3265, 3057, 1577, 1467, 1375, 1296, 1129, 1072, 1004, 797 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[C_{29}H_{23}N_4O_3S]^+$:507.149; found:507.149.

(E)-N-(1-Ethyl-3-((2-hydroxynaphthalen-1-yl)diazenyl)-1H-indol-2-yl)-4-methylbenzenesulfonamide(3g)




Blacksolid (120 mg, 99%); m.p. 156.3-157.5°C; 1H NMR (400 MHz, $CDCl_3$) δ 12.31 (b, 1H), 11.32 (s, 1H), 7.89 (d, $J = 8.0$ Hz, 2H), 7.70 - 7.66 (m, 2H), 7.51 (d, $J = 8.8$ Hz, 1H), 7.38 - 7.34 (m, 1H), 7.26 - 7.12 (m, 6H), 7.04 - 6.95 (m, 2H), 4.61 (q, $J = 7.2$ Hz, 2H), 2.25 (s, 3H), 1.52 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 147.0, 144.0, 139.5, 139.4, 129.9, 129.2, 128.7, 128.5, 127.8, 127.7, 127.2, 127.1, 126.6, 125.5, 124.0, 123.7, 121.4, 121.0, 119.9, 119.0, 118.5, 110.8, 40.7, 21.7, 13.6; IR (KBr) ν 3452, 3057, 2973, 1576, 1547, 1465, 1358, 1283, 1146, 1084, 816, 739 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[C_{27}H_{25}N_4O_3S]^+$:485.164; found:485.164.

(E)-N-(3-((2-Hydroxynaphthalen-1-yl)diazenyl)-1-isopropyl-1H-indol-2-yl)-4-methylbenzenesulfonamide(3h)



Blackpowder (116 mg, 93%); m.p. 153.3-154.2°C; ^1H NMR (400 MHz, CDCl_3) δ 12.55 (s, 1H), 10.09 (b, 1H), 8.01 (d, $J = 7.6$ Hz, 1H), 7.92 - 7.90 (m, 1H), 7.75 - 7.73 (m, 1H), 7.65 - 7.59 (m, 4H), 7.39 - 7.34 (m, 3H), 7.30 (t, $J = 7.6$ Hz, 1H), 7.10 (d, $J = 8.8$ Hz, 1H), 6.91 (d, $J = 8.0$ Hz, 2H), 5.54 (m, 1H), 1.96 (s, 3H), 1.74 (d, $J = 7.2$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 149.3, 144.6, 137.1, 136.0, 135.2, 130.6, 129.6, 129.2, 128.6, 128.5, 127.7, 127.3, 126.1, 125.8, 125.6, 124.2, 123.3, 121.3, 120.4, 120.3, 119.8, 113.7, 49.1, 21.4, 20.9; IR (neat) v 3200, 3056, 2978, 1746, 1574, 1538, 1463, 1374, 1280, 1146, 1086, 910 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{28}\text{H}_{27}\text{N}_4\text{O}_3\text{S}]^+$:499.180; found:499.180.


(E)-N-(3-((2-Hydroxynaphthalen-1-yl)diazenyl)-1-phenyl-1H-indol-2-yl)-4-methylbenzenesulfonamide(3i)



Blackpowder (125 mg, 94%); m.p. 169.3-170.2°C; ^1H NMR (400 MHz, CDCl_3) δ 12.14 (b, 1H), 11.74 (s, 1H), 7.86 - 7.84 (m, 1H), 7.71 (d, $J = 8.0$ Hz, 1H), 7.63 (d, $J = 8.4$ Hz, 2H), 7.58 - 7.53 (m, 4H), 7.47 - 7.45 (m, 2H), 7.37 (d, $J = 8.4$ Hz, 1H), 7.30 - 7.22 (m, 3H), 7.16 (d, $J = 9.2$ Hz, 1H), 7.11 - 7.06 (m, 3H), 6.74 - 6.72 (m, 1H), 2.24 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 147.7, 143.7, 141.5, 139.4, 135.7, 129.8, 129.7, 129.6, 129.4, 128.7, 128.6, 128.5, 127.6, 127.3, 127.0, 126.9, 126.3, 124.3, 123.9, 122.0, 120.4, 120.0, 119.2, 119.1, 111.6, 21.6; IR (neat) v 3203, 3061, 2920, 1573, 1548, 1499, 1377, 1302, 1150, 1087, 909, 734 cm^{-1} ; MALDI-TOF-MS


(DHB)calcd for $[C_{31}H_{25}N_4O_3S]^+$:533.164; found:533.164.

(E)-N-(1-Benzyl-3-((2-hydroxynaphthalen-1-yl)diazenyl)-1H-indol-2-yl)-4-methylbenzenesulfonamide(3j)



Redpowder (134 mg, 98%); m.p. 174.9-175.8°C; 1H NMR (400 MHz, $(CD_3)_2SO$) δ 12.54 (s, 1H), 11.40 (b, 1H), 8.60 (d, $J = 8.4$ Hz, 1H), 8.36 (d, $J = 8.4$ Hz, 1H), 7.93 - 7.89 (m, 2H), 7.68 (t, $J = 7.6$ Hz, 1H), 7.55 - 7.45 (m, 4H), 7.38-7.25 (m, 5H), 7.19 (d, $J = 8.0$ Hz, 3H), 7.01 (d, $J = 8.0$ Hz, 2H), 5.63 (s, 2H), 1.68 (s, 3H); ^{13}C NMR (100 MHz, $(CD_3)_2SO$) δ 149.2, 144.2, 137.3, 136.3, 134.7, 134.2, 132.7, 132.2, 129.8, 129.6, 129.1, 128.7, 128.5, 128.1, 128.0, 128.0, 127.4, 127.2, 125.1, 124.5, 123.9, 122.1, 121.7, 120.1, 117.7, 112.2, 46.4, 20.8; IR (KBr) ν 3452, 3060, 2920, 1571, 1464, 1349, 1296, 1167, 1087, 1051, 811 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[C_{32}H_{27}N_4O_3S]^+$:547.180; found:547.180.


(E)-N-(5-Chloro-3-((2-hydroxynaphthalen-1-yl)diazenyl)-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide(3k)



Graypowder (120 mg, 95%); m.p. 183.2-184.5°C; 1H NMR (500 MHz, $(CD_3)_2SO$) δ 12.55 (s, 1H), 11.34 (b, 1H), 8.52 (d, $J = 8.5$ Hz, 1H), 8.32 (s, 1H), 7.92 (t, $J = 8.5$ Hz, 2H), 7.69 - 7.67 (m, 2H), 7.50 (d, $J = 8.0$ Hz, 2H), 7.47 - 7.44 (m, 2H), 7.19 (d, $J = 9.0$ Hz, 1H), 7.07 (d, $J = 8.0$ Hz, 2H), 3.72 (s, 3H), 1.76 (s, 3H); ^{13}C NMR (125 MHz, $(CD_3)_2SO$) δ 149.3, 144.3, 136.4, 135.4, 133.8, 132.8, 132.1, 129.9, 129.4, 128.8,


128.6, 128.1, 127.4, 127.0, 124.8, 124.5, 121.3, 120.9, 120.2, 118.1, 113.5, 30.6, 20.9; IR (KBr) ν 3452, 3066, 2923, 1580, 1469, 1359, 1285, 1145, 1122, 1085, 926, 805 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₆H₂₂ClN₄O₃S]⁺:505.110; found:505.109.

(E)-N-(5-Bromo-3-((2-hydroxynaphthalen-1-yl)diazenyl)-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide(3l)



Nut-brownpowder (125 mg, 91%); m.p. 185.6-186.5°C; ¹H NMR (500 MHz, (CD₃)₂SO) δ 12.53 (s, 1H), 11.35 (b, 1H), 8.51 - 8.48 (m, 2H), 7.92 (t, *J* = 8.0 Hz, 2H), 7.68 - 7.62 (m, 2H), 7.56 (dd, *J* = 8.5, 1.5 Hz, 1H), 7.51 - 7.46 (m, 3H), 7.19 (d, *J* = 9.0 Hz, 1H), 7.07 (d, *J* = 8.0 Hz, 2H), 3.72 (s, 3H), 1.76 (s, 3H); ¹³C NMR (125 MHz, (CD₃)₂SO) δ 149.3, 144.3, 136.4, 135.3, 134.1, 132.8, 132.1, 129.9, 129.4, 128.9, 128.6, 128.1, 127.3, 127.3, 126.8, 124.5, 124.0, 121.3, 120.2, 118.7, 116.1, 113.8, 30.5, 20.9; IR (KBr) ν 3451, 3155, 3060, 1578, 1467, 1358, 1284, 1143, 1120, 1085, 922, 804 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₆H₂₂BrN₄O₃S]⁺:549.059; found:549.060.


(E)-N-(3-((2-Hydroxynaphthalen-1-yl)diazenyl)-5-methoxy-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide(3m)



Reddish brownpowder (123 mg, 98%); m.p. 183.5-184.2°C; ¹H NMR (500 MHz, (CD₃)₂SO) δ 12.66 (s, 1H), 11.21 (b, 1H), 8.63 (d, *J* = 8.0 Hz, 1H), 7.94 – 7.86 (m,


3H), 7.65 (t, $J = 7.5$ Hz, 1H), 7.55 - 7.52 (m, 3H), 7.45 (t, $J = 7.5$ Hz, 1H), 7.18 (d, $J = 8.5$ Hz, 1H), 7.11 (d, $J = 8.0$ Hz, 2H), 7.05 (dd, $J = 8.5, 2.0$ Hz, 1H), 3.90 (s, 3H), 3.67 (s, 3H), 1.84 (s, 3H); ^{13}C NMR (125 MHz, $(\text{CD}_3)_2\text{SO}$) δ 157.0, 149.2, 144.2, 136.7, 134.4, 132.1, 132.0, 130.2, 129.9, 129.3, 128.8, 128.5, 127.9, 127.7, 127.3, 124.4, 121.5, 120.1, 117.7, 114.2, 112.6, 104.0, 55.7, 30.4, 21.0; IR (KBr) ν 3437, 2924, 2853, 1578, 1488, 1368, 1282, 1140, 1122, 1084, 936, 805 cm^{-1} ; MALDI-TOF-MS (DHB) calcd for $[\text{C}_{27}\text{H}_{25}\text{N}_4\text{O}_4\text{S}]^+$: 501.159; found: 501.159.

(E)-Methyl 3-hydroxy-4-((1-methyl-2-(4-methylphenylsulfonamido)-1H-indol-3-yl)diazenyl)-2-naphthoate (3n)




Redsolid (120 mg, 91%); m.p. 203.0-204.4°C; ^1H NMR (600 MHz, CDCl_3) δ 13.17 (s, 1H), 9.69 (s, 1H), 9.13 (d, $J = 8.4$ Hz, 1H), 8.08 (s, 1H), 8.00 (d, $J = 7.8$ Hz, 2H), 7.72 - 7.68 (m, 2H), 7.54 - 7.51 (m, 1H), 7.35 - 7.31 (m, 4H), 7.22 - 7.20 (m, 1H), 7.07 (d, $J = 7.8$ Hz, 1H), 4.03 (s, 3H), 4.00 (s, 3H), 2.51 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 170.0, 148.2, 145.5, 145.5, 143.4, 141.8, 140.9, 130.2, 129.6, 129.3, 128.0, 127.9, 127.7, 127.7, 127.6, 124.6, 124.0, 123.8, 123.3, 123.1, 118.6, 113.0, 109.9, 52.8, 33.3, 21.8; IR (KBr) ν 2950, 2925, 2849, 1685, 1576, 1546, 1462, 1438, 1384, 1308, 1209, 1145, 1108, 1085 cm^{-1} ; MALDI-TOF-MS (DHB) calcd for $[\text{C}_{28}\text{H}_{25}\text{N}_4\text{O}_5\text{S}]^+$: 529.154; found: 529.154.

(E)-Methyl 6-hydroxy-5-((1-methyl-2-(4-methylphenylsulfonamido)-1H-indol-3-yl)diazenyl)-2-naphthoate (3o)



Redsolid (111 mg, 84%); m.p. 177.3-178.5°C; ¹H NMR (600 MHz, CDCl₃) δ 12.58 (b, 1H), 11.39 (s, 1H), 8.36 (d, *J* = 1.2 Hz, 1H), 7.95 (d, *J* = 8.4 Hz, 2H), 7.61 (d, *J* = 7.8 Hz, 1H), 7.55 (d, *J* = 9.0 Hz, 1H), 7.42 (d, *J* = 9.0 Hz, 1H), 7.40 - 7.37 (m, 1H), 7.29 (d, *J* = 7.8 Hz, 2H), 7.24 (t, *J* = 7.8 Hz, 1H), 7.17 (d, *J* = 8.4 Hz, 1H), 7.14 (d, *J* = 7.8 Hz, 1H), 6.73 (b, 1H), 4.02 (s, 3H), 3.97 (s, 3H), 2.38 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 167.1, 148.5, 144.6, 143.8, 139.6, 131.7, 130.2, 128.5, 128.4, 128.4, 127.6, 127.4, 127.0, 126.5, 125.2, 124.3, 121.0, 118.9, 118.2, 110.5, 52.4, 33.6, 21.7; IR (KBr) ν 2949, 2923, 2852, 1717, 1625, 1575, 1466, 1436, 1384, 1285, 1203, 1145, 1109, 1085 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₈H₂₅N₄O₅S]⁺:529.154; found:529.154.

(E)-N-(3-((10-Hydroxyphenanthren-9-yl)diazenyl)-1-methyl-1H-indol-2-yl)-4-methylbenzenesulfonamide(3p)




Red-brown solid (84 mg, 64%); m.p. 169.0-170.2°C; ¹H NMR (600 MHz, CDCl₃) δ 13.21 (s, 1H), 11.32 (b, 1H), 8.52 (t, *J* = 7.8 Hz, 2H), 8.41 – 8.40 (m, 1H), 7.85 (d, *J* = 7.2 Hz, 1H), 7.75 (d, *J* = 7.8 Hz, 2H), 7.67 - 7.61 (m, 2H), 7.47 - 7.39 (m, 3H), 7.29 (t, *J* = 7.2 Hz, 1H), 7.25 - 7.24 (m, 1H), 7.20 (t, *J* = 7.8 Hz, 1H), 7.03 (d, *J* = 7.8 Hz, 2H), 4.00 (s, 3H), 2.06 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 148.9, 144.3, 140.6, 139.2, 138.7, 130.9, 129.7, 128.6, 127.7, 127.3, 127.2, 127.0, 126.9, 126.0, 124.8, 124.5, 124.1, 123.7, 123.2, 122.7, 120.5, 120.0, 119.6, 119.2, 110.5, 32.6, 21.5; IR (neat) ν

2917, 2842, 1586, 1459, 1426, 1373, 1334, 1281, 1215, 1146, 1102, 1081 cm⁻¹; HRMS (ESI)calcd for [C₃₀H₂₃N₄O₃S]⁺:519.1496; found:519.1511.

methyl


2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)-2-phenylacetate(4a)



A yellow powder (86 mg, 72%); m.p. 126.8-127.7°C; ¹H NMR (500 MHz, CDCl₃) δ 11.46 (d, *J* = 7.0 Hz, 1H), 7.91 (d, *J* = 8.0 Hz, 2H), 7.55 (d, *J* = 7.5 Hz, 1H), 7.32 - 7.27 (m, 2H), 7.23 - 7.14 (m, 5H), 7.04 (d, *J* = 8.0 Hz, 1H), 6.92 (d, *J* = 7.5 Hz, 2H), 5.34 (d, *J* = 7.0 Hz, 1H), 3.96 (s, 3H), 3.67 (s, 3H), 2.42 (s, 3H) ppm; ¹³C NMR (125 MHz, CDCl₃) δ 170.5, 148.5, 142.7, 141.7, 141.2, 135.1, 129.6, 129.2, 128.8, 127.8, 127.7, 127.3, 126.7, 123.9, 123.2, 118.6, 109.8, 68.9, 52.9, 33.1, 21.8 ppm; IR (neat) ν 2952, 1747, 1574, 1538, 1494, 1464, 1375, 1284, 1146, 1087, 1005, 911, 788 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₅H₂₅N₄O₄S]⁺:477.159; found:477.159.

methyl


2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)-2-(p-tolyl)acetate (4b)



A yellow powder (76 mg, 62%); m.p. 126.8-127.5°C; ¹H NMR (400 MHz, CDCl₃) δ 11.44 (d, *J* = 7.2 Hz, 1H), 7.92 (d, *J* = 8.0 Hz, 2H), 7.55 (d, *J* = 7.2 Hz, 1H), 7.32 -

7.28 (m, 1H), 7.24 (d, J = 8.0 Hz, 2H), 7.15 (t, J = 7.6 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 2H), 6.80 (d, J = 8.0 Hz, 2H), 5.30 (d, J = 7.2 Hz, 1H), 3.96 (s, 3H), 3.66 (s, 3H), 2.43 (s, 3H), 2.33 (s, 3H) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ 170.6, 148.5, 142.7, 141.7, 141.2, 138.7, 132.2, 129.8, 129.5, 127.6, 127.6, 127.2, 126.7, 123.9, 123.2, 118.5, 109.8, 68.7, 52.8, 33.1, 21.8, 21.5 ppm; IR (neat) ν 2953, 2924, 1746, 1581, 1538, 1493, 1464, 1375, 1283, 1146, 1086, 1005, 748, 788 cm^{-1} ; MALDI-TOF-MS (DHB) calcd for $[\text{C}_{26}\text{H}_{27}\text{N}_4\text{O}_4\text{S}]^+$: 491.175; found: 491.175.


2-(4-methoxyphenyl)-2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hydr azinyl)acetate(4c)



A yellow powder (72 mg, 57%); m.p. 126.8-127.5°C; ^1H NMR (400 MHz, CDCl_3) δ 11.40 (d, J = 6.8 Hz, 1H), 7.90 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 7.2 Hz, 1H), 7.32 - 7.28 (m, 1H), 7.23 (d, J = 8.0 Hz, 2H), 7.15 (td, J = 7.6 Hz, 0.4 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.85 (d, J = 8.8 Hz, 2H), 6.70 (d, J = 8.8 Hz, 2H), 5.28 (d, J = 6.8 Hz, 1H), 3.95 (s, 3H), 3.80 (s, 3H), 3.67 (s, 3H), 2.43 (s, 3H) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ 170.8, 160.0, 148.5, 142.7, 141.6, 141.2, 129.5, 128.6, 127.6, 127.6, 127.0, 126.6, 123.9, 123.2, 118.5, 114.5, 109.8, 68.3, 55.5, 52.8, 33.1, 21.7 ppm; IR (neat) ν 2954, 2923, 1746, 1578, 1538, 1463, 1374, 1281, 1251, 1146, 1083, 1033, 910, 788 cm^{-1} ; MALDI-TOF-MS (DHB) calcd for $[\text{C}_{26}\text{H}_{27}\text{N}_4\text{O}_5\text{S}]^+$: 507.170; found: 507.170.

methyl


2-([1,1'-biphenyl]-4-yl)-2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hy drazinyl)acetate(4d)



A yellow powder (102 mg, 74%); m.p. 165.9-166.3°C; ¹H NMR (400 MHz, CDCl₃) δ 11.52 (d, *J* = 7.2 Hz, 1H), 7.94 (d, *J* = 8.0 Hz, 2H), 7.56 (t, *J* = 7.2 Hz, 3H), 7.48 - 7.45 (m, 2H), 7.42 (m, 3H), 7.31 (td, *J* = 7.2 Hz, 0.4Hz, 1H), 7.24 (d, *J* = 8.0 Hz, 2H), 7.18 - 7.14 (m, 1H), 7.05 (d, *J* = 8.0 Hz, 1H), 7.00 (d, *J* = 8.0 Hz, 2H), 5.39 (d, *J* = 7.2 Hz, 1H), 3.97 (s, 3H), 3.70 (s, 3H), 2.31 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 170.5, 148.5, 142.8, 141.8, 141.7, 141.2, 140.5, 134.1, 129.6, 129.2, 128.0, 127.9, 127.8, 127.8, 127.7, 127.3, 126.7, 124.0, 123.2, 118.6, 109.8, 68.6, 52.9, 33.2, 21.7 ppm; IR (neat) ν 2953, 2923, 1744, 1581, 1534, 1464, 1373, 1283, 1145, 1084, 1043, 1004 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₃₁H₂₉N₄O₄S]⁺:553.190; found: 553.190.

methyl

2-(4-fluorophenyl)-2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)acetate(4e)




A yellow foamed solid (100 mg, 81%); m.p. 60.8-61.7°C; ¹H NMR (400 MHz, CDCl₃) δ 11.39 (d, *J* = 6.8 Hz, 1H), 7.89 (d, *J* = 8.4 Hz, 2H), 7.55 (dd, *J* = 7.6 Hz, 0.4Hz, 1H), 7.32 (td, *J* = 7.6 Hz, 1.2Hz, 1H), 7.23(d, *J* = 8.0 Hz, 2H), 7.15 (td, *J* = 7.6 Hz, 0.8Hz, 1H), 7.05 (d, *J* = 8.0 Hz, 1H), 6.94 - 6.84 (m, 4H), 5.31 (d, *J* = 7.2 Hz, 1H), 3.96 (s, 3H), 3.69 (s, 3H), 2.43 (s, 3H) ppm; ¹³C NMR (125 MHz, CDCl₃) δ 170.4, 162.9 (d, ¹J_{CF} = 250 Hz), 148.5, 142.9, 141.5 (d, ³J_{CF} = 8 Hz), 130.9 (d, ⁴J_{CF} = 3 Hz), 129.5,

129.2, 129.1, 128.1, 127.9, 126.6, 124.0, 123.0, 118.6, 116.1 (d, $^2J_{\text{CF}} = 22$ Hz), 109.8, 67.9, 53.0, 33.1, 21.7 ppm; IR (neat) ν 2954, 2920, 1747, 1583, 1538, 1510, 1464, 1375, 1283, 1224, 1146, 1086, 1045, 788 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{25}\text{H}_{24}\text{FN}_4\text{O}_4\text{S}]^+$:495.150; found:495.150.

methyl


2-(4-chlorophenyl)-2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)acetate(4f)



A yellow powder (105 mg, 82%); m.p. 131.5-132.6°C; ^1H NMR (400 MHz, CDCl_3) δ 11.41 (d, $J = 6.8$ Hz, 1H), 7.90 (d, $J = 8.0$ Hz, 2H), 7.55 (d, $J = 7.6$ Hz, 1H), 7.32 (td, $J = 8.0$ Hz, 1.2Hz, 1H), 7.23 (d, $J = 8.0$ Hz, 2H), 7.15 (d, $J = 8.4$ Hz, 3H), 7.06 (d, $J = 8.0$ Hz, 1H), 6.87 (d, $J = 8.4$ Hz, 2H), 5.30 (d, $J = 7.2$ Hz, 1H), 3.96 (s, 3H), 3.68 (s, 3H), 2.44 (s, 3H) ppm; ^{13}C NMR (125 MHz, CDCl_3) δ 170.2, 148.5, 143.0, 141.9, 141.1, 134.9, 133.6, 129.5, 129.3, 128.7, 128.3, 127.9, 126.6, 124.0, 123.0, 118.7, 109.9, 68.0, 53.0, 33.1, 21.8 ppm; IR (neat) ν 2950, 2925, 1746, 1584, 1538, 1491, 1464, 1376, 1283, 1146, 1086, 1015, 788 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{25}\text{H}_{24}\text{ClN}_4\text{O}_4\text{S}]^+$:511.120; found:511.120.

methyl


2-(4-bromophenyl)-2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)acetate(4g)



A yellow powder (115 mg, 83%); m.p. 139.2-140.4°C; ¹H NMR (400 MHz, CDCl₃) δ 11.41 (d, *J* = 6.8 Hz, 1H), 7.90 (d, *J* = 8.4 Hz, 2H), 7.54 (d, *J* = 7.6 Hz, 1H), 7.33 - 7.30 (m, 3H), 7.24 (d, *J* = 8.0 Hz, 2H), 7.18 - 7.14 (m, 1H), 7.05 (d, *J* = 8.0 Hz, 1H), 6.81 (d, *J* = 8.4 Hz, 2H), 5.29 (d, *J* = 7.2 Hz, 1H), 3.96 (s, 3H), 3.68 (s, 3H), 2.45 (s, 3H) ppm; ¹³C NMR (125 MHz, CDCl₃) δ 170.1, 148.5, 143.0, 141.9, 141.1, 134.1, 132.3, 129.5, 128.9, 128.4, 128.0, 126.7, 124.0, 123.0, 123.0, 118.7, 109.9, 68.1, 53.0, 33.2, 21.9 ppm; IR (neat) ν 3021, 2953, 1747, 1584, 1538, 1464, 1374, 1284, 1146, 1086, 1011, 749 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₅H₂₄BrN₄O₄S]⁺:555.070; found:555.070.

methyl

2-(3-chlorophenyl)-2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)acetate(4h)




A yellow foamed solid (121 mg, 95%); m.p. 57.8-58.6°C; ¹H NMR (400 MHz, CDCl₃) δ 11.45 (d, *J* = 6.8 Hz, 1H), 7.91 (d, *J* = 8.0 Hz, 2H), 7.54 (d, *J* = 7.2 Hz, 1H), 7.34 - 7.27 (m, 2H), 7.23 (d, *J* = 8.0 Hz, 2H), 7.18 - 7.11 (m, 2H), 7.07 - 7.04 (m, 2H), 6.81 (d, *J* = 8.0 Hz, 1H), 5.31 (d, *J* = 7.2 Hz, 1H), 3.96 (s, 3H), 3.69 (s, 3H), 2.41 (s, 3H) ppm; ¹³C NMR (125 MHz, CDCl₃) δ 169.8, 148.5, 142.8, 141.9, 141.0, 137.3, 135.0, 130.4, 129.6, 129.1, 128.3, 127.9, 127.6, 126.5, 125.4, 124.0, 123.0, 118.7, 109.8, 77.5, 77.3, 77.0, 68.2, 53.0, 33.1, 21.8 ppm; IR (neat) ν 2953, 1747, 1583, 1538, 1491, 1464, 1375, 1284, 1224, 1146, 1086, 1045, 1005, 788 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₅H₂₄ClN₄O₄S]⁺:511.120; found:511.120.

methyl

2-(3-methoxyphenyl)-2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hydr


azinyl)acetate(4i)



A yellow foamed solid (103 mg, 81%); m.p. 48.9-49.6°C; ¹H NMR (400 MHz, CDCl₃) δ 11.42 (d, *J* = 6.8 Hz, 1H), 7.89 (d, *J* = 8.4 Hz, 2H), 7.56 (d, *J* = 7.2 Hz, 1H), 7.30 (td, *J* = 7.6 Hz, 1.2 Hz, 1H), 7.20 - 7.14 (m, 3H), 7.11 - 7.03 (m, 2H), 6.84 - 6.81 (m, 1H), 6.65 – 6.64 (m, 1H), 6.46 (d, *J* = 7.6 Hz, 1H), 5.31 (d, *J* = 6.8 Hz, 1H), 3.96 (s, 3H), 3.73 (s, 3H), 3.67 (s, 3H), 2.40 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 170.4, 160.1, 148.5, 142.7, 141.7, 141.0, 136.5, 130.2, 129.5, 127.8, 127.7, 126.5, 123.9, 123.2, 119.3, 118.6, 114.5, 113.2, 109.8, 68.8, 55.5, 52.9, 33.1, 21.8 ppm; IR (neat) ν 2954, 2926, 1747, 1574, 1538, 1463, 1375, 1282, 1145, 1085, 1044, 1005, 900, 788 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₆H₂₇N₄O₅S]⁺:507.170; found:507.170.

methyl

2-(2-methoxyphenyl)-2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)acetate(4j)




A yellow powder (46 mg, 36%); m.p. 116.0-117.1°C; ¹H NMR (400 MHz, CDCl₃) δ 11.37 (d, *J* = 7.2 Hz, 1H), 7.90 (d, *J* = 8.0 Hz, 2H), 7.58 (d, *J* = 7.2 Hz, 1H), 7.31 - 7.27 (m, 2H), 7.22(d, *J* = 8.0 Hz, 2H), 7.15 (td, *J* = 7.6 Hz, 0.8 Hz, 1H), 7.03 (d, *J* = 8.0 Hz, 1H), 6.78 (d, *J* = 8.0 Hz, 1H), 6.74 - 6.73 (m, 2H), 5.68 (d, *J* = 7.2 Hz, 1H), 3.94 (s, 3H), 3.68 (s, 3H), 3.62 (s, 3H), 2.44 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 171.0, 156.9, 148.8, 142.5, 141.5, 141.3, 130.2, 129.6, 128.7, 127.4, 127.1, 126.6,

123.9, 123.8, 123.4, 121.0, 118.5, 111.3, 109.7, 64.1, 55.7, 52.8, 33.3, 21.8 ppm; IR (neat) ν 2951, 2840, 1746, 1580, 1537, 1464, 1374, 1282, 1144, 1086, 1045, 911, 804 cm⁻¹; MALDI-TOF-MS (DHB) calcd for [C₂₆H₂₇N₄O₅S]⁺: 507.170; found: 507.170.


methyl

2-(2-chlorophenyl)-2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)acetate(4k)



A yellow powder (105 mg, 82%); m.p. 134.3-135.2°C; ¹H NMR (400 MHz, CDCl₃) δ 11.43 (d, *J* = 6.8 Hz, 1H), 7.93 (d, *J* = 8.4 Hz, 2H), 7.56 (d, *J* = 7.2 Hz, 1H), 7.34 - 7.27 (m, 3H), 7.25 - 7.21 (m, 2H), 7.16 (td, *J* = 7.6 Hz, 0.8 Hz, 1H), 7.05 - 7.01 (m, 2H), 6.75 - 6.73 (m, 1H), 5.76 (d, *J* = 6.8 Hz, 1H), 3.96 (s, 3H), 3.69 (s, 3H), 2.44 (s, 3H) ppm; ¹³C NMR (125 MHz, CDCl₃) δ 169.9, 148.6, 142.7, 141.8, 141.2, 14.0, 133.7, 130.2, 130.1, 129.6, 129.1, 128.0, 127.8, 127.4, 126.8, 123.9, 123.1, 118.7, 109.8, 66.1, 53.0, 33.2, 21.8 ppm; IR (neat) ν 2947, 1748, 1582, 1537, 1465, 1374, 1283, 1145, 1105, 1086, 1044, 1005, 788 cm⁻¹; MALDI-TOF-MS (DHB) calcd for [C₂₅H₂₄ClN₄O₄S]⁺: 511.120; found: 511.120.

(Z)-4-methyl-N-((Z)-1-methyl-3-(2-(2-oxo-1-phenylbutyl)hydrazone)indolin-2-ylidene)benzenesulfonamide(4l)




A yellow solid (93 mg, 76%); m.p. 129.7-130.8°C; ¹H NMR (500 MHz, CDCl₃)

δ11.45 (d, $J = 7.0$ Hz, 1H), 7.91 (d, $J = 8.0$ Hz, 2H), 7.55 (d, $J = 7.5$ Hz, 1H), 7.31 - 7.26 (m, 2H), 7.22-7.14 (m, 5H), 7.04 (d, $J = 8.0$ Hz, 1H), 6.93 (d, $J = 7.5$ Hz, 2H), 5.31 (d, $J = 7.0$ Hz, 1H), 4.20 - 4.08 (m, 2H), 3.95 (s, 3H), 2.41 (s, 3H), 1.19 (t, $J = 7.0$ Hz, 3H) ppm; ^{13}C NMR (125 MHz, CDCl_3) δ 170.0, 148.5, 142.6, 141.7, 141.2, 135.2, 129.6, 129.1, 128.7, 127.7, 127.6, 127.3, 126.6, 123.9, 123.2, 118.5, 109.8, 69.0, 62.0, 33.1, 21.8, 14.3 ppm; IR (neat) v 2925, 1740, 1581, 1537, 1465, 1373, 1296, 1146, 1086, 1003, 788 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₆H₂₇N₄O₃S]⁺:491.175; found:491.175.

isopropyl


2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)-2-phenylacetate (4m)



A yellow foamed solid (69 mg, 55%); m.p. 45.5-46.4°C; ^1H NMR (400 MHz, CDCl_3) δ 11.43 (d, $J = 7.2$ Hz, 1H), 7.90 (d, $J = 8.4$ Hz, 2H), 7.55 (dd, $J = 7.2, 0.4$ Hz, 1H), 7.32 - 7.28 (m, 2H), 7.21-7.14 (m, 5H), 7.04 (d, $J = 8.0$ Hz, 1H), 6.93 (d, $J = 7.2$ Hz, 2H), 5.28 (d, $J = 6.8$ Hz, 1H), 5.05 - 4.95 (m, 1H), 3.96 (s, 3H), 2.41 (s, 3H), 1.22 (d, $J = 6.4$ Hz, 3H), 1.10 (d, $J = 6.4$ Hz, 3H) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ 169.5, 148.5, 142.6, 141.6, 141.2, 135.3, 129.6, 129.0, 128.7, 127.6, 127.6, 127.3, 126.6, 123.9, 123.3, 118.5, 109.8, 69.7, 69.1, 33.1, 21.9, 21.8, 21.6 ppm; IR (neat) v 2926, 1738, 1574, 1538, 1464, 1375, 1284, 1146, 1086, 1004, 803 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₇H₂₉N₄O₄S]⁺:505.190; found:505.190.

phenyl


2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)-2-phenylacetate(4n)



A yellow foamed solid (118 mg, 88%); m.p. 67.9-68.7°C; ¹H NMR (400 MHz, CDCl₃) δ 11.55 (d, *J* = 7.2 Hz, 1H), 7.87 (d, *J* = 8.4 Hz, 2H), 7.59 (d, *J* = 7.2 Hz, 1H), 7.37 - 7.29 (m, 4H), 7.25 - 7.22 (m, 3H), 7.19 - 7.15 (m, 1H), 7.12 (d, *J* = 8.0 Hz, 2H), 7.06 - 7.02 (m, 3H), 6.96 - 6.93 (m, 2H), 5.55 (d, *J* = 7.2 Hz, 1H), 3.96 (s, 3H), 2.35 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 168.6, 150.5, 148.5, 142.7, 141.8, 141.0, 134.7, 129.7, 129.6, 129.3, 129.1, 128.2, 127.9, 127.4, 126.6, 126.5, 124.0, 123.1, 121.3, 118.6, 109.9, 69.0, 33.1, 21.8 ppm; IR (neat) v 2925, 1762, 1583, 1538, 1491, 1464, 1375, 1284, 1191, 1146, 1086, 788 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₃₀H₂₇N₄O₄S]⁺:539.175; found:539.175.

benzyl

2-((Z)-2-((Z)-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)-2-phenylacetate(4o)




A yellow powder (117 mg, 85%); m.p. 118.5-119.7°C; ¹H NMR (400 MHz, CDCl₃) δ 11.55 (d, *J* = 7.2 Hz, 1H), 7.85 (d, *J* = 8.0 Hz, 2H), 7.54 (d, *J* = 7.2 Hz, 1H), 7.32 - 7.26 (m, 5H), 7.20 - 7.17 (m, 2H), 7.16 - 7.10 (m, 5H), 7.04 (d, *J* = 8.0 Hz, 1H), 6.87 (d, *J* = 7.2 Hz, 2H), 5.38 (d, *J* = 7.2 Hz, 1H), 5.17 - 5.09 (m, 2H), 3.95 (s, 3H), 2.36 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 170.0, 148.5, 142.6, 141.7, 141.1, 135.5, 134.8, 129.5, 129.1, 128.8, 128.6, 128.2, 127.9, 127.7, 127.3, 126.6, 123.9, 123.1, 118.6, 109.8, 69.0, 67.4, 33.1, 21.8 ppm; IR (neat) v 2956, 2925, 1744, 1581, 1538,

1495, 1464, 1375, 1284, 1146, 1086, 1004, 788 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₃₁H₂₉N₄O₄S]⁺:553.190; found:553.188.

methyl


2-((Z)-2-((Z)-1-ethyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)-2-phenylacetate (4p)



A yellow powder (120 mg, 98%); m.p. 113.9-114.7°C; ¹H NMR (400 MHz, CDCl₃) δ 11.46 (d, *J* = 7.2 Hz, 1H), 7.92 (d, *J* = 8.4 Hz, 2H), 7.56 (d, *J* = 7.6 Hz, 1H), 7.32 - 7.26 (m, 2H), 7.23 - 7.13(m, 5H), 7.07 (d, *J* = 8.0 Hz, 1H), 6.90 (d, *J* = 7.2 Hz, 2H), 5.33 (d, *J* = 7.2 Hz, 1H), 4.61 - 4.51 (m, 2H), 3.69 (s, 3H), 2.41 (s, 3H), 1.54 (t, *J* = 7.2 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 170.5, 146.9, 142.7, 141.2, 140.5, 135.1, 129.6, 129.1, 128.8, 127.8, 127.7, 127.3, 126.6, 123.8, 123.6, 118.6, 110.2, 69.1, 52.9, 40.4, 21.8, 13.4ppm; IR (neat) ν 2977, 2952, 1747, 1574, 1537, 1463, 1373, 1283, 1197, 1147, 1086, 1010, 821 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₆H₂₇N₄O₄S]⁺:491.175; found:491.175.

methyl

2-phenyl-2-((Z)-2-((Z)-1-phenyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)acetate(4q)




A yellow powder (129 mg, 96%); m.p. 116.5-117.4°C; ¹H NMR (400 MHz, CDCl₃)

δ 11.62 (d, J = 7.2 Hz, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.62 - 7.55 (m, 6H), 7.31 - 7.27 (m, 1H), 7.21 - 7.12 (m, 6H), 6.95 (d, J = 7.2 Hz, 2H), 6.54 - 6.52 (m, 1H), 5.39 (d, J = 7.2 Hz, 1H), 3.69 (s, 3H), 2.36 (s, 3H) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ 170.5, 147.5, 143.4, 142.3, 141.5, 135.8, 135.1, 130.1, 129.8, 129.5, 129.4, 129.2, 128.9, 127.7, 127.6, 127.3, 126.5, 124.0, 122.7, 118.4, 111.1, 69.1, 52.9, 21.8 ppm; IR (neat) ν 2953, 2925, 1746, 1574, 1531, 1496, 1455, 1374, 1299, 1149, 1088, 809, 749 cm^{-1} ; MALDI-TOF-MS (DHB) calcd for $[\text{C}_{30}\text{H}_{27}\text{N}_4\text{O}_4\text{S}]^+$: 539.175; found: 539.175.


methyl

2-((Z)-2-((Z)-1-methyl-2-((naphthalen-2-ylsulfonyl)imino)indolin-3-ylidene)hydrazinyl)-2-phenylacetate(4r)



A yellow solid (115 mg, 90%); m.p. 139.2-140.4°C; ^1H NMR (400 MHz, CDCl_3) δ 11.40 (d, J = 6.8 Hz, 1H), 8.87 (d, J = 1.2 Hz, 1H), 8.03 (dd, J = 8.4, 1.2 Hz, 1H), 7.98 (d, J = 7.6 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.67 - 7.59 (m, 2H), 7.56 (d, J = 7.6 Hz, 1H), 7.31 (td, J = 7.6, 1.2 Hz, 1H), 7.16 (td, J = 7.2, 0.8 Hz, 1H), 7.06 (d, J = 8.0 Hz, 1H), 7.01 - 6.96 (m, 1H), 6.73 - 6.67 (m, 4H), 5.26 (d, J = 7.2 Hz, 1H), 4.00 (s, 3H), 3.53 (s, 3H) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ 170.4, 148.5, 141.6, 140.9, 134.9, 134.7, 132.4, 129.7, 129.4, 128.9, 128.8, 128.6, 128.2, 127.7, 127.6, 127.5, 127.2, 127.0, 124.0, 123.2, 122.8, 118.6, 109.9, 68.9, 52.8, 33.1 ppm; IR (neat) ν 3051, 2950, 1742, 1574, 1534, 1492, 1462, 1377, 1294, 1144, 1045, 905, 793 cm^{-1} ; MALDI-TOF-MS (DHB) calcd for $[\text{C}_{28}\text{H}_{25}\text{N}_4\text{O}_4\text{S}]^+$: 513.159; found: 513.159.


methyl 2-((Z)-2-((Z)-2-(((4-chlorophenyl)sulfonyl)imino)-1-methylindolin-3-ylidene)hydrazinyl)-2-phenylacetate(4s)



A yellow powder (114 mg, 92%); m.p. 129.6-131.7°C; ^1H NMR (400 MHz, CDCl_3) δ 11.28 (d, $J = 7.2$ Hz, 1H), 7.93 (d, $J = 8.4$ Hz, 2H), 7.57 (d, $J = 7.2$ Hz, 1H), 7.37 - 7.30 (m, 4H), 7.27 - 7.23 (m, 3H), 7.19 - 7.15 (m, 1H), 7.06 (d, $J = 8.0$ Hz, 1H), 6.97 (d, $J = 7.6$ Hz, 1H), 5.34 (d, $J = 6.8$ Hz, 1H), 3.95 (s, 3H), 3.70 (s, 3H) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ 170.5, 148.5, 142.4, 141.6, 138.5, 134.8, 129.3, 129.2, 129.2, 128.1, 127.8, 127.7, 127.3, 124.1, 123.1, 118.7, 109.9, 68.6, 52.9, 33.1 ppm; IR (neat) ν 2953, 2925, 1746, 1581, 1538, 1464, 1378, 1302, 1148, 1087, 1005, 799 cm^{-1} ; MALDI-TOF-MS (DHB) calcd for $[\text{C}_{24}\text{H}_{22}\text{ClN}_4\text{O}_4\text{S}]^+$: 497.105; found: 497.105.

methyl

2-((Z)-2-((4-fluorophenyl)sulfonyl)imino)-1-methylindolin-3-ylidene)hydr azinyl)-2-phenylacetate(4t)




A yellow powder (109 mg, 91%); m.p. 113.4-114.6°C; ^1H NMR (400 MHz, CDCl_3) δ 11.31 (d, $J = 6.8$ Hz, 1H), 8.03 - 7.99 (m, 2H), 7.56 (d, $J = 7.2$ Hz, 1H), 7.34 - 7.29 (m, 2H), 7.25 - 7.22 (m, 2H), 7.16 (t, $J = 7.6$ Hz, 1H), 7.06 (t, $J = 8.4$ Hz, 3H), 6.97 (d, $J = 7.2$ Hz, 2H), 5.34 (d, $J = 6.8$ Hz, 1H), 3.95 (s, 3H), 3.69 (s, 3H) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ 170.5, 164.9 (d, $^1J_{\text{CF}} = 250$ Hz), 148.4, 141.6, 140.0 (d, $^4J_{\text{CF}} = 3$ Hz), 135.0, 129.3, 129.3, 129.2 (d, $^3J_{\text{CF}} = 11$ Hz), 127.8, 127.7, 127.3, 124.1, 123.1, 118.6, 116.0 (d, $^2J_{\text{CF}} = 22$ Hz), 109.9, 68.6, 52.9, 33.1 ppm; IR (neat) ν 2956, 2924, 2854, 1745, 1580, 1531, 1463, 1377, 1260, 1086, 1029, 800 cm^{-1} ; MALDI-TOF-MS

(DHB)calcd for [C₂₄H₂₂FN₄O₄S]⁺:481.134; found:481.134.

methyl


2-((Z)-2-((Z)-2-(((4-methoxyphenyl)sulfonyl)imino)-1-methylindolin-3-ylidene)hydrazinyl)-2-phenylacetate(4u)



A yellow powder (96 mg, 78%); m.p. 122.4-123.6°C; ¹H NMR (400 MHz, CDCl₃) δ 11.47 (d, *J* = 7.2 Hz, 1H), 7.95 (d, *J* = 8.8 Hz, 2H), 7.56 (d, *J* = 7.2 Hz, 1H), 7.32 - 7.26 (m, 2H), 7.22 - 7.14 (m, 3H), 7.04 (d, *J* = 8.0 Hz, 1H), 6.95 (d, *J* = 7.2 Hz, 2H), 6.90 (d, *J* = 8.8 Hz, 2H), 5.34 (d, *J* = 7.2 Hz, 1H), 3.96 (s, 3H), 3.86 (s, 3H), 3.68 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 170.6, 162.6, 148.4, 141.7, 136.0, 135.0, 129.2, 128.9, 128.7, 127.8, 127.7, 127.3, 123.9, 123.1, 118.6, 114.1, 109.8, 68.8, 55.8, 52.9, 33.1 ppm; IR (neat) ν 2953, 2837, 1746, 1581, 1538, 1496, 1464, 1375, 1287, 1144, 808 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₅H₂₅N₄O₅S]⁺:493.154; found:493.154.

methyl

2-((Z)-2-((Z)-1-methyl-2-((methylsulfonyl)imino)indolin-3-ylidene)hydrazinyl)-2-phenylacetate(4v)




A yellow solid (71 mg, 71%); m.p. 143.9-144.6°C; ¹H NMR (400 MHz, CDCl₃) δ 12.02 (d, *J* = 6.0 Hz, 1H), 7.51 (d, *J* = 7.6 Hz, 1H), 7.41 - 7.38 (m, 5H), 7.29 - 7.25 (m,

1H), 7.12 (td, $J = 7.6, 0.8$ Hz, 1H), 7.00 (d, $J = 8.0$ Hz, 1H), 5.50 (d, $J = 6.0$ Hz, 1H), 3.84 (s, 3H), 3.78 (s, 3H), 3.28 (s, 3H) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ 170.7, 148.5, 141.6, 136.6, 129.4, 129.2, 127.9, 127.7, 127.5, 123.9, 123.0, 118.6, 109.7, 67.5, 53.2, 44.5, 32.9 ppm; IR (neat) ν 2953, 2923, 2852, 1737, 1582, 1538, 1459, 1375, 1280, 1107, 807 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{19}\text{H}_{21}\text{N}_4\text{O}_4\text{S}]^+$:401.128; found:401.128.

methyl


2-((Z)-2-((Z)-5-fluoro-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)-2-ph enylacetate(4w)



A yellow powder (104 mg, 84%); m.p. 116.8-117.5°C; ^1H NMR (400 MHz, CDCl_3) δ 11.54 (d, $J = 7.2$ Hz, 1H), 7.91 (d, $J = 8.4$ Hz, 2H), 7.29 (t, $J = 7.6$ Hz, 1H), 7.26 - 7.23 (m, 3H), 7.21 - 7.17 (m, 2H), 7.01 - 6.94 (m, 2H), 6.91 (d, $J = 7.6$ Hz, 2H), 5.32 (d, $J = 6.8$ Hz, 1H), 3.94 (s, 3H), 3.68 (s, 3H), 2.42 (s, 3H) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ 170.3, 160.3 (d, $^1J_{\text{CF}} = 240$ Hz), 148.8 (d, $^5J_{\text{CF}} = 0.8$ Hz), 142.8, 141.0, 137.6 (d, $^4J_{\text{CF}} = 1.4$ Hz), 134.9, 129.6, 129.2, 128.9, 127.3, 127.0 (d, $^4J_{\text{CF}} = 3.5$ Hz), 126.7, 124.6 (d, $^3J_{\text{CF}} = 9.7$ Hz), 114.2 (d, $^2J_{\text{CF}} = 24.7$ Hz), 110.7 (d, $^3J_{\text{CF}} = 8.7$ Hz), 105.7 (d, $^2J_{\text{CF}} = 25.8$ Hz), 69.0, 52.9, 33.3, 21.8 ppm; IR (neat) ν 3029, 2955, 1747, 1583, 1538, 1480, 1363, 1281, 1146, 1086, 803 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{25}\text{H}_{24}\text{FN}_4\text{O}_4\text{S}]^+$:495.150; found:495.150.

methyl


2-((Z)-2-((Z)-5-chloro-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)-2-ph enylacetate(4x)



A yellow powder (96 mg, 75%); m.p. 119.4-120.7°C; ¹H NMR (400 MHz, CDCl₃) δ 11.52 (d, *J* = 6.8 Hz, 1H), 7.90 (d, *J* = 8.4 Hz, 2H), 7.52 (d, *J* = 2.0 Hz, 1H), 7.30 (t, *J* = 7.6 Hz, 1H), 7.26 - 7.23 (m, 3H), 7.21 - 7.17 (m, 2H), 6.96 (d, *J* = 8.4 Hz, 1H), 6.92 - 6.90 (m, 2H), 5.32 (d, *J* = 7.2 Hz, 1H), 3.94 (s, 3H), 3.68 (s, 3H), 2.43 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 170.2, 148.5, 142.9, 140.9, 140.0, 134.8, 129.7, 129.6, 129.2, 129.0, 127.3, 127.3, 126.7, 126.5, 124.6, 118.6, 110.8, 69.0, 53.0, 33.3, 21.8 ppm; IR (neat) ν 3030, 2953, 1747, 1583, 1538, 1455, 1361, 1284, 1147, 1087, 919, 805 cm⁻¹; MALDI-TOF-MS (DHB)calcd for [C₂₅H₂₄ClN₄O₄S]⁺:511.120; found: 511.120.

methyl

2-((Z)-2-((Z)-5-bromo-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)-2-phenylacetate(4y)




A yellow powder (108 mg, 78%); m.p. 114.9-115.7°C; ¹H NMR (400 MHz, CDCl₃) δ 11.52 (d, *J* = 6.8 Hz, 1H), 7.90 (d, *J* = 8.0 Hz, 2H), 7.67 (d, *J* = 2.0 Hz, 1H), 7.40 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.32 - 7.28 (m, 1H), 7.24 (d, *J* = 8.0 Hz, 2H), 7.21 - 7.17 (m, 2H), 6.93 - 6.89 (m, 3H), 5.32 (d, *J* = 7.2 Hz, 1H), 3.94 (s, 3H), 3.68 (s, 3H), 2.43 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 170.2, 148.3, 142.9, 140.9, 140.4, 134.8, 130.1, 129.6, 129.2, 129.0, 127.3, 126.7, 126.4, 125.0, 121.5, 117.1, 111.3, 69.0, 53.0, 33.3, 21.9 ppm; IR (neat) ν 2953, 1747, 1575, 1538, 1455, 1360, 1284, 1146, 1087, 916, 804

cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{25}\text{H}_{24}\text{BrN}_4\text{O}_4\text{S}]^+$:555.070; found:555.070.


methyl

2-((Z)-2-((Z)-5-methoxy-1-methyl-2-(tosylimino)indolin-3-ylidene)hydrazinyl)-2-phenylacetate(4z)



A orange foamed solid (123 mg, 89%); m.p. 58.7-59.9°C; ^1H NMR (400 MHz, CDCl_3) δ 11.47 (d, $J = 7.2$ Hz, 1H), 7.91 (d, $J = 8.0$ Hz, 2H), 7.30 - 7.26 (m, 1H), 7.22 (d, $J = 8.0$ Hz, 2H), 7.18 (t, $J = 7.6$ Hz, 2H), 7.10 (d, $J = 2.4$ Hz, 1H), 6.95 - 6.90 (m, 3H), 6.85 (dd, $J = 8.8\text{Hz}, 2.0\text{Hz}$, 1H), 5.33 (d, $J = 7.2$ Hz, 1H), 3.92 (s, 3H), 3.82 (s, 3H), 3.67 (s, 3H), 2.42 (s, 3H) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ 170.5, 157.1, 148.5, 142.6, 141.2, 135.7, 135.1, 129.5, 129.2, 128.8, 127.9, 127.3, 126.6, 124.2, 114.3, 110.6, 103.4, 68.9, 56.1, 52.9, 33.2, 21.8 ppm; IR (neat) ν 2953, 1747, 1583, 1538, 1486, 1367, 1285, 1145, 1086, 911, 791 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{26}\text{H}_{27}\text{N}_4\text{O}_5\text{S}]^+$:507.170; found:507.170.


8-Fluoro-10-methyl-9-tosyl-9,10-dihydro-8H-naphtho[1'',2'':4',5'][1,3,2]oxazaborolo[3',2':2,3][1,2,4,3]triazaborinino[5,6-b]indol-16-ium-8-uide(7a)



Blacksolid (118 mg, 95%); m.p. 208.6-209.8°C; ^1H NMR (400 MHz, CDCl_3) δ 8.68 (d, $J = 8.4$ Hz, 1H), 8.12 - 8.10 (m, 1H), 7.78 (d, $J = 8.0$ Hz, 1H), 7.70 (d, $J = 8.8$ Hz, 1H), 7.62 - 7.58 (m, 1H), 7.54 - 7.46 (m, 3H), 7.44 - 7.40 (m, 1H), 7.14 (d, $J = 8.8$ Hz, 1H),


7.10 (d, $J = 8.4$ Hz, 2H), 6.48 (d, $J = 8.0$ Hz, 2H), 4.11 (s, 3H), 1.52 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 160.0, 143.8, 138.2, 135.4, 134.1, 133.3, 129.3, 129.2, 129.2, 128.6, 126.3, 126.1, 125.3, 124.7, 123.8, 122.6, 122.1, 119.4, 116.3, 111.8, 34.7, 20.8; IR (neat) ν 3062, 2925, 1568, 1515, 1463, 1371, 1240, 1169, 1089, 933 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{26}\text{H}_{21}\text{BFN}_4\text{O}_3\text{S}]^+$:499.141; found:499.156.

8-Fluoro-10-methyl-9-(phenylsulfonyl)-9,10-dihydro-8H-naphtho[1'',2'':4',5'][1,3,2]oxazaborolo[3',2':2,3][1,2,4,3]triazaborinino[5,6-b]indol-16-iium-8-uide(7b)



Deep-bluesolid (113 mg, 93%); m.p. 184.5-185.8°C; ^1H NMR (400 MHz, CDCl_3) δ 8.70 (d, $J = 8.4$ Hz, 1H), 8.11 (d, $J = 7.2$ Hz, 1H), 7.77 (d, $J = 8.0$ Hz, 1H), 7.66 (d, $J = 8.8$ Hz, 1H), 7.61 - 7.57 (m, 1H), 7.54 - 7.46 (m, 3H), 7.43 - 7.39 (m, 1H), 7.29 - 7.27 (m, 2H), 7.10 (d, $J = 8.8$ Hz, 1H), 6.80 - 6.71 (m, 3H), 4.12 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.7, 138.4, 138.3, 134.0, 133.4, 132.4, 130.8, 129.4, 129.2, 128.6, 128.3, 126.3, 126.2, 125.4, 124.7, 123.7, 122.5, 122.0, 119.3, 116.0, 111.8, 34.9; IR (neat) ν 3055, 2950, 1626, 1568, 1516, 1463, 1373, 1284, 1171, 1086, 935 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{25}\text{H}_{19}\text{BFN}_4\text{O}_3\text{S}]^+$:485.125; found:485.125.


8-Fluoro-10-methyl-9-(methylsulfonyl)-9,10-dihydro-8H-naphtho[1'',2'':4',5'][1,3,2]oxazaborolo[3',2':2,3][1,2,4,3]triazaborinino[5,6-b]indol-16-iium-8-uide (7c)



Deep-bluesolid (97 mg, 92%); m.p. 157.4-158.8°C; ^1H NMR (400 MHz, CDCl_3) δ



9.03 (d, $J = 8.4$ Hz, 1H), 8.12 - 8.10 (m, 1H), 7.86 (t, $J = 9.6$ Hz, 2H), 7.70 (t, $J = 7.6$ Hz, 1H), 7.51 - 7.39 (m, 5H), 3.96 (s, 3H), 3.00 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.0, 138.3, 134.0, 133.9, 130.8, 129.9, 129.7, 129.4, 126.4, 125.7, 124.9, 124.1, 122.9, 122.1, 119.2, 116.0, 111.7, 42.6, 35.2; IR (neat) ν 3054, 2926, 1626, 1569, 1520, 1464, 1370, 1284, 1239, 1166, 1069, 915 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{20}\text{H}_{17}\text{BFN}_4\text{O}_3\text{S}]^+$:423.110; found:423.110.


13-Bromo-8-fluoro-10-methyl-9-tosyl-9,10-dihydro-8H-naphtho[1'',2'':4',5'][1,3,2]oxazaborolo[3',2':2,3][1,2,4,3]triazaborinino[5,6-b]indol-16-ium-8-uide(7d)







Blacksolid (127 mg, 88%); m.p. 213.4-214.5°C; ^1H NMR (400 MHz, CDCl_3) δ 8.64 (d, $J = 8.4$ Hz, 1H), 8.23 (d, $J = 1.6$ Hz, 1H), 7.79 (d, $J = 8.0$ Hz, 1H), 7.74 (d, $J = 9.2$ Hz, 1H), 7.65 - 7.59 (m, 2H), 7.46 - 7.42 (m, 1H), 7.37 (d, $J = 8.4$ Hz, 1H), 7.14 (d, $J = 8.8$ Hz, 1H), 7.08 (d, $J = 8.4$ Hz, 2H), 6.49 (d, $J = 8.0$ Hz, 2H), 4.09 (s, 3H), 1.52 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 160.8, 144.0, 136.7, 135.3, 134.3, 129.8, 129.6, 129.4, 129.2, 128.9, 128.7, 126.1, 125.6, 123.8, 123.5, 122.6, 122.0, 118.0, 116.4, 113.2, 34.8, 20.8; IR (neat) ν 3060, 2947, 1569, 1505, 1462, 1367, 1285, 1170, 1091, 1038 cm^{-1} ; MALDI-TOF-MS (DHB)calcd for $[\text{C}_{26}\text{H}_{20}\text{BBrFN}_4\text{O}_3\text{S}]^+$:577.051; found:577.021.



The ^1H and ^{13}C NMR Spectra of compound 3a-p, 4a-z, 7a-d








































































































































































Figure S1 Absorption spectra of **3** in DCM




Figure S2 Absorption spectra of **7** in DCM

